Leading the worldwide fight to treat and cure Tay-Sachs, Canavan, GM1 and Sandhoff diseases
Donate
Information to help advocate for legislation and other related advocacy issues.
Modified on 12 April 2021 1167 downloads
2021 January NTSAD FDA Late Onset GM2 Patient Listening session.pdf
Members of the Late Onset Tay-Sachs and Sandhoff (LOTSS) community participated in a listening session with the U.S. Food and Drug Administration (FDA), so regulators could better understand the impact of heterogenous disease on the lives of individuals and their families.
2000 downloads
US-Senate-Twitter-handles.pdf
3698 downloads
GG-Advocacy-Toolkit-Capitol-Hill.pdf
Username
Password
Remember Me